Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
Healthcare
$1.18 +3.09%
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
52W Low $1.41High $4.34
Volume 4.26M
Average 0.64M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$18.47M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$28.45M
FY 2025 · Annual
+118.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 839.37K | 1.53M | 3.26M | 2.39M | 1.8M |
| Change in Working Capital | (329.78K) | 1.51M | 442.23K | (1.08M) | (1.01M) |
| Accounts Receivables | (63.35K) | 3.63K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (521.39K) | 1.07M | (643.16K) | 274.89K | (468.61K) |
| Other Working Capital | 254.96K | 444.52K | 1.09M | (1.36M) | (537.91K) |
| Other Non-Cash Items | 999.87K | (206.86K) | (383.19K) | 143.52K | 804.94K |
| Operating Cash Flow | (12.37M) | (14.69M) | (18.87M) | (18.87M) | (18.47M) |
| Capital Expenditures | (94.21K) | (118.95K) | (15.36K) | (22.49K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (17.74M) | (1.96M) | 0 | 0 |
| Sales of Investments | 0 | 3.08M | 12.19M | 5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (94.21K) | (14.77M) | 10.22M | 4.98M | 0 |
| Debt Repayment | (21.95K) | (78.77K) | (89.07K) | (90.88K) | (96.5K) |
| Common Stock Issued | 42.63M | 0 | 12.73M | 13.21M | 28.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (841.27K) | 0 | 0 | (109.36K) | 0 |
| Financing Cash Flow | 41.77M | (78.77K) | 12.64M | 13.01M | 28.45M |
| Effect of Forex Changes | 100.78K | (23.8K) | 488.4K | (527.17K) | 469.43K |
| Net Change in Cash | 29.41M | (29.57M) | 4.49M | (1.41M) | 10.46M |
| Free Cash Flow | (12.46M) | (14.81M) | (18.88M) | (18.9M) | (18.47M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$20.2M
+ D&A$94.0K
+ Stock-Based Comp$1.8M
+ Deferred Tax$0
- Working Capital-$1.0M
+ Other Non-Cash$804.9K
= Operating Cash Flow-$18.5M
- Capex$0
= Free Cash Flow-$18.5M
Analysis
FY2025 free cash flow is -$18.5M. FCF conversion is 91.6% of net income. Operating cash flow was -$18.5M, with capex of $0. The largest bridge item is Stock-Based Comp at $1.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 17, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 30, 2026 |
Does GANX generate free cash flow?
Gain Therapeutics, Inc. (GANX) generated -$18.47M of free cash flow in fiscal 2025.
How much operating cash flow does GANX produce?
Operating cash flow was -$18.47M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.